223 related articles for article (PubMed ID: 27194008)
1. Inflammatory biomarkers and risk of cancer in 84,000 individuals from the general population.
Allin KH; Bojesen SE; Nordestgaard BG
Int J Cancer; 2016 Oct; 139(7):1493-500. PubMed ID: 27194008
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
Thomsen M; Ingebrigtsen TS; Marott JL; Dahl M; Lange P; Vestbo J; Nordestgaard BG
JAMA; 2013 Jun; 309(22):2353-61. PubMed ID: 23757083
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey.
Bittoni MA; Focht BC; Clinton SK; Buckworth J; Harris RE
Int J Oncol; 2015 Oct; 47(4):1537-44. PubMed ID: 26323323
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory biomarker score and cancer: A population-based prospective cohort study.
Morrison L; Laukkanen JA; Ronkainen K; Kurl S; Kauhanen J; Toriola AT
BMC Cancer; 2016 Feb; 16():80. PubMed ID: 26860264
[TBL] [Abstract][Full Text] [Related]
5. Association of inflammatory markers with colorectal cancer incidence in the atherosclerosis risk in communities study.
Prizment AE; Anderson KE; Visvanathan K; Folsom AR
Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):297-307. PubMed ID: 21217085
[TBL] [Abstract][Full Text] [Related]
6. Prediagnostic circulating markers of inflammation and risk of prostate cancer.
Toriola AT; Laukkanen JA; Kurl S; Nyyssönen K; Ronkainen K; Kauhanen J
Int J Cancer; 2013 Dec; 133(12):2961-7. PubMed ID: 23754532
[TBL] [Abstract][Full Text] [Related]
7. Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort.
Swede H; Hajduk AM; Sharma J; Rawal S; Rasool H; Vella AT; Tobet RE; Stevens RG
Int J Cancer; 2014 Apr; 134(8):1862-70. PubMed ID: 24122448
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease.
Thomsen M; Dahl M; Lange P; Vestbo J; Nordestgaard BG
Am J Respir Crit Care Med; 2012 Nov; 186(10):982-8. PubMed ID: 22983959
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory serum markers and risk and severity of prostate cancer: The PROCA-life study.
Stikbakke E; Richardsen E; Knutsen T; Wilsgaard T; Giovannucci EL; McTiernan A; Eggen AE; Haugnes HS; Thune I
Int J Cancer; 2020 Jul; 147(1):84-92. PubMed ID: 31583707
[TBL] [Abstract][Full Text] [Related]
10. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study.
Allin KH; Nordestgaard BG; Flyger H; Bojesen SE
Breast Cancer Res; 2011 Jun; 13(3):R55. PubMed ID: 21639875
[TBL] [Abstract][Full Text] [Related]
11. Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients.
Wulaningsih W; Holmberg L; Garmo H; Malmstrom H; Lambe M; Hammar N; Walldius G; Jungner I; Van Hemelrijck M
Carcinogenesis; 2015 Oct; 36(10):1121-8. PubMed ID: 26130675
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study.
Siemes C; Visser LE; Coebergh JW; Splinter TA; Witteman JC; Uitterlinden AG; Hofman A; Pols HA; Stricker BH
J Clin Oncol; 2006 Nov; 24(33):5216-22. PubMed ID: 17114654
[TBL] [Abstract][Full Text] [Related]
13. Plasma C-reactive protein, genetic risk score, and risk of common cancers in the Atherosclerosis Risk in Communities study.
Prizment AE; Folsom AR; Dreyfus J; Anderson KE; Visvanathan K; Joshu CE; Platz EA; Pankow JS
Cancer Causes Control; 2013 Dec; 24(12):2077-87. PubMed ID: 24036889
[TBL] [Abstract][Full Text] [Related]
14. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer.
Allin KH; Bojesen SE; Nordestgaard BG
J Clin Oncol; 2009 May; 27(13):2217-24. PubMed ID: 19289618
[TBL] [Abstract][Full Text] [Related]
15. Inflammation and future risk of symptomatic heart failure in patients with stable coronary artery disease.
Eisen A; Benderly M; Behar S; Goldbourt U; Haim M
Am Heart J; 2014 May; 167(5):707-14. PubMed ID: 24766981
[TBL] [Abstract][Full Text] [Related]
16. The relation between systemic inflammation and incident cancer in patients with stable cardiovascular disease: a cohort study.
Van't Klooster CC; Ridker PM; Hjortnaes J; van der Graaf Y; Asselbergs FW; Westerink J; Aerts JGJV; Visseren FLJ
Eur Heart J; 2019 Dec; 40(48):3901-3909. PubMed ID: 31504409
[TBL] [Abstract][Full Text] [Related]
17. Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study.
Ahmadi-Abhari S; Luben RN; Wareham NJ; Khaw KT
Eur J Epidemiol; 2013 Jul; 28(7):541-50. PubMed ID: 23821244
[TBL] [Abstract][Full Text] [Related]
18. Preoperative plasma fibrinogen, but not D-dimer might represent a prognostic factor in non-metastatic colorectal cancer: A prospective cohort study.
Hong T; Shen D; Chen X; Wu X; Hua D
Cancer Biomark; 2017; 19(1):103-111. PubMed ID: 28269756
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein levels are not associated with increased risk for colorectal cancer in women.
Zhang SM; Buring JE; Lee IM; Cook NR; Ridker PM
Ann Intern Med; 2005 Mar; 142(6):425-32. PubMed ID: 15767620
[TBL] [Abstract][Full Text] [Related]
20. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer.
Allin KH; Nordestgaard BG
Crit Rev Clin Lab Sci; 2011; 48(4):155-70. PubMed ID: 22035340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
